At SF-8 evaluation, patients receiving SI showed a score of 58 vs 42 in the SFGC group; thus, a better quality of life and wellness perception was recorded in the SI group. Fievez V, Plapied L, Plaideau C et al (2010) In vitro identification of targeting ligands of human M cells by phage display. Int J Pharm 394:35–42. https://doi.org/10.1016/j.ijpharm.2010.04.023 Patients were consecutively randomized (random 1:1) to receive oral Sucrosomial iron (SI) or i.v. sodium ferric gluconate. Lisääntyneen raudan tarpeen syy tulee aina selvittää. Keskustele terveydenhuollon ammattilaisen kanssa ennen käytön aloittamista.

Kruske SG, Ruben AR, Brewster DR (1999) An iron treatment trial in an aboriginal community: improving non-adherence. J Paediatr Child Health 35:153 poate fi administrat in orice situatie in care este necesara suplimentarea cu fier, chiar si pe perioade indelungate.Gulec S, Anderson GJ, Collins JF (2014) Mechanistic and regulatory aspects of intestinal iron absorption. Am J Physiol Gastrointest Liver Physiol 307:G397–G409 Gastrointestinal side effects, mainly of low level, were reported in 27% of patients from the SI group, in accordance with data already reported in the literature [ 47]. It is not surprising that the totality of patients with side effects are 80 years old or older. In fact, 40% of elderly patients show gastrointestinal side effects [ 48, 62] and probably the high number of octogenarians with gastrointestinal side effects is only due to the low number of patients in our study. On the other hand, it is noteworthy that in patients taking Sucrosomial iron with food, gastrointestinal side effects are reduced to almost one-third (only 10%), a markedly lower percentage in comparison to previous studies. Skikne BS, Cook JD (1992) Effect of enhanced erythropoiesis on iron absorption. J Lab Clin Med 120:746–751 WHO (2001) Iron deficiency anemia assessment, prevention, and control: a guide for programme managers. Geneva: World Health Organization WHO/NHD/01.3

The median cost of treatment in each group was calculated taking into account the overall cost of all therapy for each patient during the observation period, then dividing this cost for the months of follow-up to obtain average cost per month of follow-up per patient. In each group, the median of the average cost per month of follow-up per patient was then calculated. This provides a valuation of the costs, unrelated to the exact cost of the drug, but linked to the outcome and efficacy of the therapeutic strategy during the observation period. A nu se utiliza în caz de hipersensibilitate la oricare dintre ingrediente sau de intoleranță la proteinele din lapte. Produsul conține proteine din lapte.Musallam KM, Tamim HM, Richards T et al (2011) Preoperative anaemia and postoperative outcomes in non-cardiac surgery: a retrospective cohort study. Lancet 378:1396–1407 At a median time of 12 months after enrollment, the median value of ferritin (ng/ml) at end of treatment was 260 ( R: 150–320) in the SI group vs 18 ( R: 5–56) in the SFGC group ( p = 0.01).

Poate fi utilizat în orice situație în care aportul de fier din dietă este scăzut, în cazul în care necesarul de fier al organismului este mare (anemie feriprivă, pierderi acute sau cronice de sânge) sau în care absorbția intestinală a fierului este afectată; Poate fi administrat în orice situație în care este necesară suplimentarea cu fier, chiar și pe perioade îndelungate. Wish JB (2006) Assessing iron status: beyond serum ferritin and transferrin saturation. Clin J Am Soc Nephrol Suppl 1:S4–S8. https://doi.org/10.2215/CJN.01490506 Guyton and Hall Textbook of medical physiology (2011) Digestion and absorption in the gastrointestinal tract, Saunders 12th Ed, Chap. 65este o sursa inovatoare de fier, cu biodisponibilitate crescuta, sub forma unui complex Sucrosomial de pirofosfat de fier; Tolkien Z, Stecher L, Mander AP, Pereira DI, Powell JJ (2015) Ferrous sulfate supplementation causes significant gastrointestinal side-effects in adults: a systematic review and meta-analysis. PLoS One 10:e0117383. https://doi.org/10.1371/journal.pone.0117383 Sabora Pharma ja kumppanit tallentavat sivustolta tietoja laitteelle ja / tai käyttävät laitteella olevia tietoja, kuten laitetunnisteita, edellä mainittuihin tarkoituksiin Säilytä tuotetta huoneenlämmössä, kuivassa paikassa. Vältä altistumista lämmönlähteille ja auringonvalolle. Ainesosat